Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06141668 · ClinicalTrials.gov registry record · NA
Optimal Stimulation Parameters to Disrupt Epileptiform Activity
A NA study of Refractory Epilepsy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06141668: Recruiting NA study of Refractory Epilepsy, sponsored by Massachusetts General Hospital.
NCT06141668 is a NA study of Refractory Epilepsy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 61-participant average among 4 other Refractory Epilepsy trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06141668, a NA study of Refractory Epilepsy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We will compare the performance of stimulation parameters identified in rodent models to the recommended parameters for neuromodulation used in clinical practice.
Primary Outcome
Spike ripple rate \~ 1 + condition + (1\|subject) This is a within-subject repeated-measures study design analyzed using a generalized linear mixed-effects model. Effect size for each arm (+/- 95% confidence interval) reported below. Treatment response was assessed using the change in spike ripple rate (SR rate) relative to each subject's baseline. For each subject, the treatment response at each stimulation frequency (1 Hz, 20 Hz, 40 Hz, 140 Hz, and 200 Hz) was calculated by subtracting the s
Conditions Studied
Interventions
- OTHER Neurostimulation
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT06141668 shows while recruiting
NCT06141668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 61-participant average among 4 other Refractory Epilepsy trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Refractory Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Neurostimulation is the first listed.
NCT06141668 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06141668 about?
NCT06141668 is a clinical study titled "Optimal Stimulation Parameters to Disrupt Epileptiform Activity". Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We will compare the performance of stimulation parame...
What is the current status of trial NCT06141668?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-06-13. Estimated completion is 2026-11-30.
What conditions does trial NCT06141668 study?
This clinical trial studies the following conditions: Refractory Epilepsy.
What interventions are being tested in trial NCT06141668?
The interventions under investigation include: Neurostimulation (OTHER).
Who is sponsoring clinical trial NCT06141668?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06141668 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
RECRUITING · NA
-
Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application
RECRUITING · NA
-
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
RECRUITING · Phase 2
-
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
RECRUITING · Early Phase 1
-
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI